Technology area: Biotechnology & Pharmaceuticals
21 pending office actions • 12 art units • 20 examiners • 0 of 21 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
MEDIMMUNE Limited has 22 pending office actions in Biotechnology & Pharmaceuticals. Those actions involve 21 distinct examiners across 12 art units, showing broad allocation throughout the relevant examination organization.
BRISTOL, LYNN ANNE is associated with 2 pending matters, making that examiner a point of recurring activity within the portfolio. The remaining matters are spread widely, so counsel should avoid relying on a single examiner strategy and instead track each art-unit record closely.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (10%) |
| §103 only | 1 (5%) |
| §112 only | 3 (14%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 10 (48%) |
| Multi-statute (no §101) | 4 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 2 | 63.4% | +39.8% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| CHATTIN, AMY MARIE | 1 | 72.2% | +45.7% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| VAN DRUFF, SYDNEY | 1 | 55.3% | +32.0% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18360542 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | HAMA, JOANNE | 42d |
| 18351821 | METHODS FOR EXPANDING T CELL POPULATIONS | CANDELARIA, JULIANA IRENE | 60d |
| 19075308 | METHODS OF TREATING CORONARY ARTERY DISEASE | DUFFY, PATRICIA ANN | — |
| 18633844 | PD-1/TIGIT BINDING PROTEINS FOR CANCER TREATMENT | ALLEN, MARIANNE P | — |
| 18630379 | Optimized CD3 Antigen Binding Domains | GUSTILO, ESTELLA M | — |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | VAN DRUFF, SYDNEY | — |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | — |
| 17913483 | METHODS FOR TREATING ATOPIC DERMATITIS AND RELATED DISORDERS | ESSEX, LAURA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783463 | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 | ROGERS, ERIC JASON | 3d overdue |
| 18360542 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | HAMA, JOANNE | 42d |
| 19075308 | METHODS OF TREATING CORONARY ARTERY DISEASE | DUFFY, PATRICIA ANN | — |
| 18671167 | PD-1/TIM-3 BINDING PROTEINS FOR TREATMENT OF NSCLC and cHL | CUNNINGCHEN, KATHLEEN MARY | — |
| 18633844 | PD-1/TIGIT BINDING PROTEINS FOR CANCER TREATMENT | ALLEN, MARIANNE P | — |
| 18630379 | Optimized CD3 Antigen Binding Domains | GUSTILO, ESTELLA M | — |
| 18414892 | BCMA Monoclonal Antibody-Drug Conjugate | BRISTOL, LYNN ANNE | — |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | CHATTIN, AMY MARIE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 4 |
| 1647 | 3 |
| 1646 | 2 |
| 1654 | 2 |
| 1641 | 2 |
| 1675 | 2 |
| 1645 | 1 |
| 1634 | 1 |
| 1638 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19075308 | METHODS OF TREATING CORONARY ARTERY DISEASE | DUFFY, PATRICIA ANN | 1645 | §102§112Other | Non-Final OA | — | Pending | Mar 10, 2025 |
| 18671167 | PD-1/TIM-3 BINDING PROTEINS FOR TREATMENT OF NSCLC and cHL | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103DP | Non-Final OA | — | Pending | May 22, 2024 |
| 18633844 | PD-1/TIGIT BINDING PROTEINS FOR CANCER TREATMENT | ALLEN, MARIANNE P | 1647 | §103§112Other | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18630379 | Optimized CD3 Antigen Binding Domains | GUSTILO, ESTELLA M | 1646 | §101§112DP | Non-Final OA | — | Pending | Apr 09, 2024 |
| 18414892 | BCMA Monoclonal Antibody-Drug Conjugate | BRISTOL, LYNN ANNE | 1643 | §112DPOther | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | CHATTIN, AMY MARIE | 1643 | §112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18360542 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | HAMA, JOANNE | 1647 | §103Other | Non-Final OA | 42d | Pending | Jul 27, 2023 |
| 18351821 | METHODS FOR EXPANDING T CELL POPULATIONS | CANDELARIA, JULIANA IRENE | 1634 | DP | Final Rejection | 60d | Pending | Jul 13, 2023 |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | VAN DRUFF, SYDNEY | 1643 | §103§112Other | Non-Final OA | — | Pending | Mar 06, 2023 |
| 17907683 | STABILIZED IGG4 ANTIBODIES AND USES THEREOF | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17783463 | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 | ROGERS, ERIC JASON | 1638 | §112DP | Final Rejection | 3d overdue | Pending | Jun 08, 2022 |
| 18943007 | RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF | HILL, MYRON G | 1671 | §112DP | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | 1654 | §101§102§103DP | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18427293 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF | PUTTLITZ, KARL J | 1642 | §112DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18572300 | COMBINATION THERAPY USING ANTIBODY-DRUG CONJUGATES | PETERS, ALEC JON | 1641 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18557480 | METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS | CHERNYSHEV, OLGA N | 1675 | §102§112DP | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18490856 | ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287240 | AN ANTI-TSLP FAB WITH IMPROVED STABILITY | KIM, YUNSOO | 1641 | §102§112DP | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18257756 | POLYPEPTIDES AND USES THEREOF | HELLMAN, KRISTINA M | 1654 | §112Other | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | BUNNER, BRIDGET E | 1647 | §103DP | Non-Final OA | 6d | Pending | Feb 15, 2023 |
| 17913483 | METHODS FOR TREATING ATOPIC DERMATITIS AND RELATED DISORDERS | ESSEX, LAURA ANN | 1675 | §103§112Other | Final Rejection | — | Pending | Sep 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMEDIMMUNE Limited has 21 pending office actions as of October 2026, spread across 12 art units and 20 examiners.
Lynn Anne Bristol has the most, with 2 of MEDIMMUNE Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
